Generic Entry
Generic Entry is a regulatory milestone representing the first market introduction of a pharmaceutically equivalent drug product following the expiration of data or market exclusivity protections, distinguished by its reliance on the preexisting safety and efficacy data of the reference innovator product rather than independent clinical demonstration.
137
Publications
7.6K
Citations
319
Authors
183
Institutions
Publications per year
2017–2026
32
Variants
Generic Market Entry
Parents
137
1–5 of 137
319
7
h-index
6
h-index
London School of Economics and Political Science, United Kingdom
5 publications · 469 citations
5
h-index
5
h-index
5
h-index
1–5 of 319
183
Harvard University
Cambridge, United States
13 h-index
36 publications
1K citations
Duke University
Durham, United States
9 h-index
10 publications
602 citations

Brigham and Women's Hospital
Boston, United States
8 h-index
21 publications
430 citations

National Bureau of Economic Research
Cambridge, United States
7 h-index
9 publications
425 citations
Analysis Group (United States)
Boston, United States
7 h-index
16 publications
1K citations
London School of Economics and Political Science
London, United Kingdom
6 h-index
12 publications
971 citations

University of Calgary
Calgary, Canada
4 h-index
9 publications
316 citations
United States Food and Drug Administration
Silver Spring, United States
4 h-index
7 publications
122 citations
1–8 of 183
Repository · 14 publications · 341 citations
11
h-index
5 publications · 459 citations
5
h-index
5 publications · 108 citations
5
h-index
Repository · 5 publications · 318 citations
5
h-index
4 publications · 146 citations
4
h-index
1–5